PROTEINIC PHARMACOS CONTRIBUTION SYSTEM USING MEMBRANE MIMETICS.

摘要

A mixed liposomal pharmaceutical formulation with multilamellar vesicles, comprising a macromolecular pharmaceutical agent having a molecular weight greater than 1,000, water, an alkali metal lauryl sulfate in a concentration of 1 to 10% w / w of the total formulation, at least one membrane-mimetic amphiphile and at least one phospholipid, wherein the membrane-mimetic amphiphile is selected from the group consisting of pharmaceutically acceptable salts of hyaluronic acid hyaluronic acid, lauramidopropyl betain, lauramide monoisopropanolamide, sodium cocoamphopropionate, bishydroxypropyl dihydroxypropyl chloride, polioxietilendihidroxipropilestearamonio chloride, dioctadecyldimethylammonium chloride, sulfosuccinates, DEA stearamide, gamma-linoleic acid, borage oil, evening primrose oil, monoolein, sodium taurodihydrofusidate, fusidic acid, alkali metal isostearyl-lactylates, alkaline metal isostarylate s, panthenyl triacetate, cocamidopropyl PG-dimonium, stearamidopropyl PG-dimonium, amidopropyl phosphatidyl PG-dimonium borage amidopropyl phosphatidylcholine borage, polysiloxy, trihydroxy oxo cholanyl glycine and alkali metal salts thereof, octylphenoxypolyethoxyethanol chloride chloride, polyidecanol X-lauryl ether, polyidecanol X-oleyl ether, wherein X is 9 to 20, and combinations thereof, and wherein the phospholipid is selected from the group consisting of phospholipid GLA, phosphatidyldioleoylphosphatidylethanolamine, sphingomyelin, ceramides , cephalin, triolein, lecithin, saturated lecithin and lysolecithin, and combinations thereof, and in which each of the membrane mimetic amphiphilic and phospholipid is present in a concentration of 1 to 10% w / w of the total formulation, and the total concentration of membrane mimetic amphiphiles and phospholipids is less than 50% w / w of the formulation.